MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Read Here
Advertise
Sign Up
Commentary
How Hong Kong SMEs should set boundaries for agentic AI in B2B selling
Stablecoin payments are going mainstream. Hong Kong and APAC are showing how
How commercial spaces must adapt to changing consumer expectations
AI, data centres, and the coming energy supercycle in Hong Kong